Long-term follow-up results of alpha interferon therapy in chronic myelogenous leukemia at MD Anderson Cancer Center

HM Kantarjian, M Talpaz - Leukemia & lymphoma, 1993 - Taylor & Francis
Ten years ago, alpha interferon (IFN-A) was introduced as a promising modality in the
management of patients with chronic myelogenous leukemia (CML). Since then, it has been …

Biotherapy of chronic myelogenous leukemia

WE Aulitzky, C Peschel, F Schneller, C Huber - Annals of hematology, 1995 - Springer
The aim of this review is to summarize the current knowledge on the clinical results of
biotherapy of chronic myelogenous leukemia (CML) and potential mechanisms of the …

A prospective randomized study of alpha-2b interferon plus hydroxyurea or cytarabine for patients with early chronic phase chronic myelogenous leukemia: the …

FJ Giles, J Shan, S Chen, SH Advani… - Leukemia & …, 2000 - Taylor & Francis
A prospective randomized international study of 143 patients showed no apparent early
survival advantage conferred by combining cytarabine, rather than hydroxyurea, with INF as …

Effect of Interferon-α on Patients with Previously Untreated Chronic Myelogenous Leukemia in the Early Chronic Phase: Comparison between Interferon-α Continued …

T Kawatani, F Tajima, K Ishiga, H Omura, A Endo… - …, 2001 - Taylor & Francis
In order to confirm the effect of interferon-α (IFN-α) in inducing a prolonged duration of the
chronic phase (CP) on patients with chronic myelogenous leukemia (CML), we …

[引用][C] Medical management of chronic myelogenous leukemia.(Basic and Clinical Oncology/16.) M. Talpaz, HM Kantarjian (eds). Marcel Dekker, New York/Basel …

T Kovacsovics - cancer. J, 1998 - Springer

A randomized study comparing interferon (IFNα) plus low-dose cytarabine and interferon plus hydroxyurea (HU) in early chronic-phase chronic myeloid leukemia …

T Kühr, S Burgstaller, U Apfelbeck, W Linkesch… - Leukemia Research, 2003 - Elsevier
This multicenter randomized phase III study was designed to compare the efficacy and
toxicity of IFNα-2c (3.5 MU/d) in combination with either araC (10mg/m2 d1-10) or …

Hematological and cytogenetic response of interferon alpha 2b alone and combined interferon alpha plus cytarabine as a first-line treatment in chronic myeloid …

E Tothova, M Fricova, A Kafkova, N Stecova… - …, 2000 - pubmed.ncbi.nlm.nih.gov
Treatment with interferon-alpha (IFNalpha) prolongs survival in chronic myeloid leukemia
(CML). Additionally, cytarabine (AraC) can reduce the number of Ph+ metaphases …

[引用][C] Treatment of the patients with chronic myeloid leukemia

IR Gartovska, SA Guseva - Ukr J Chemother, 2004 - ifp.kiev.ua
In the article the review of the literature and our results on application of interferon alpha in
treatment chronic myeloid leukaemia is submitted.

Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic …

AM Liberati… - New England Journal …, 1994 - research.unipg.it
Background. In view of studies showing that interferon alfa was effective treatment for
chronic myeloid leukemia and that it prolonged survival, we organized a prospective …

A long term follow-up of a randomized trial comparing interferon-α with busulfan for chronic myelogenous leukemia

R Ohno, Kouseisho Leukemia Study Group - Leukemia Research, 1998 - infona.pl
To evaluate the long-term effectiveness of interferon-α (IFN-α) therapy in patients with
chronic myelogenous leukemia (CML) in chronic phase, we examined the updated …